To test the effect of capsazepine treatment in the setting of adriamycin-induced nephropathy in PON2 deficiency in vivo, we treated PON2-deficient mice as well as wildtype littermates with daily intraperitoneal injections of 20 mg/kg capsazepine or vehicle over a period of 14 days after induction of glomerular disease with adriamycin (Figure 5A). The gene discussed is PON2; the disease is kidney disorder.